Why Salesforce Stock Skyrocketed 40% Last Month

Salesforce reported fiscal Q2 adjusted EPS of $5.90 versus $3.27 consensus on $11.35 billion of revenue, ahead of the $11.32 billion estimate, with sales up roughly 11% year over year. Net income rose 87% to $3.53 billion and free cash flow climbed 81% to $1.1 billion, far above the roughly $643 million analyst target, aided in part by gains on its Anthropic investment. Management raised full-year revenue guidance to $46.1-$46.4 billion and adjusted EPS guidance to $16.67-$16.71 from $14.06-$14.12, while AI product traction and a Claude integration helped ease disruption concerns; shares rose 40% in August.

Analysis

The key underwriting distinction is recurring monetization versus financial income: the unusually large EPS upside appears materially influenced by the Anthropic investment mark, while the organic top-line guide change is comparatively modest. That creates a near-term multiple risk if sell-side models capitalize the headline EPS beat rather than normalize non-operating gains; the next two quarters need to demonstrate that Agentforce/Claude integrations convert into paid seat expansion, higher data-cloud consumption, or lower support costs. Free-cash-flow strength is constructive, but one quarter is insufficient to separate sustainable operating leverage from billing and working-capital timing.

CRM’s AI narrative shifts competitive positioning more favorably against HUBS and smaller CRM vendors, which lack comparable enterprise data estates and distribution. The more relevant competitive question is whether AI becomes a feature bundled by MSFT, ORCL, and NOW rather than a new monetization vector; if so, Salesforce may retain customers but face price-per-seat pressure and higher infrastructure expense. Contentful and Fin add cross-sell optionality, but acquisitions also complicate measurement of underlying growth and could delay margin realization over the next 6-18 months.

After a sharp rerating, the risk/reward is no longer the earnings print itself but evidence of durable AI attach rates. Consensus is likely underestimating CRM’s ability to defend its installed base with workflow-embedded AI, but overestimating how quickly that defense translates into incremental revenue. A deceleration in subscription backlog, flat AI-related net retention, or a reduction in FY revenue guidance would falsify the constructive operating thesis and likely trigger multiple compression before any EPS impact is visible.

Key Decisions for Investors

• Do not chase CRM immediately after the momentum move; establish a 1-3 month watch entry only on a post-earnings consolidation or after management discloses measurable AI monetization metrics (paid-agent adoption, consumption revenue, or net retention improvement). Target a 12-month long only if recurring growth, excluding acquired revenue, remains at or above the current low-double-digit trajectory.
• For an AI-software relative-value expression, consider long CRM / short HUBS on a 3-6 month horizon. CRM has greater enterprise distribution and data integration capacity, while HUBS is more exposed if AI functionality becomes table stakes; exit if CRM’s organic growth premium fails to emerge or HUBS sustains superior net retention.
• Use a defined-risk downside hedge rather than an outright CRM short: buy 3-6 month CRM put spreads around the next earnings date if implied volatility is not elevated. The catalyst is normalization of earnings estimates once the investment gain rolls off; the thesis is invalidated by disclosed recurring AI revenue sufficient to offset that normalization.
• Monitor MSFT, ORCL, and NOW product pricing and customer-win disclosures. Broad AI bundling by these platforms would weaken Salesforce’s ability to charge separately for agentic features and is the principal 6-18 month threat to CRM’s margin and valuation expansion.